HKEX Hang Seng Biotech Index Futures

The first exchange-traded derivatives tracking Hong Kong's biotech sector.

Hang Seng Biotech Index Futures are the first exchange-traded derivatives contracts to track the Hang Seng Biotech Index (HSBIO), launched on 16 December 2019 to track the performance of the 30 largest biotech, pharmaceuticals and medical device companies listed in Hong Kong that are eligible for Southbound Stock Connect. Trading under the code HBI on HKEX, contracts carry a multiplier of HK$50 per index point and a minimum fluctuation of one index point, and trade across 9:15 am – 12:00 noon, 1:00 pm – 4:30 pm and 5:00 pm – 3:00 am sessions.

The contracts provide investors with a unique tool to manage risk in their exposure to Hong Kong-listed biotech companies, particularly given the sector's volatility. Contracts are cash-settled, based on the average of quotations taken at five-minute intervals on the Last Trading Day.

Key Benefits

• Pioneering Biotech Sector Access
  • The first futures contracts to track the Hang Seng Biotech Index, offering direct exposure to Hong Kong's 30 largest Southbound Stock Connect-eligible biotech, pharmaceuticals and medical device companies.
     
• Targeted Risk Management
  • A unique tool to manage risk in exposure to Hong Kong-listed biotech companies, a fast-growing and volatile sector.
     
• Reliable Cash Settlement
  • Contracts settle in cash based on the average of quotations taken at five-minute intervals on the Last Trading Day.
     
• Extended Trading Hours
  • Trade across day (9:15am–12:00pm, 1:00pm–4:30pm) and after-hours (5:00pm–3:00am) sessions.
     

Contract Specifications

Source: HKEX

This advertisement has not been reviewed by the Monetary Authority of Singapore.
 

ENQUIRY FORM